{
    "clinical_study": {
        "@rank": "99041", 
        "arm_group": [
            {
                "arm_group_label": "SYL1001 eye drops dose A", 
                "arm_group_type": "Experimental", 
                "description": "Ocular topical administration of SYL1001 eye drops dose A"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Ocular topical administration of placebo eye drops"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this pilot study is to compare the analgesic effect of SYL1001 versus placebo in\n      patients with ocular pain associated with Dry Eye Syndrome. General and local tolerability\n      are also evaluated."
        }, 
        "brief_title": "Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain", 
        "condition": [
            "Ocular Pain", 
            "Dry Eye Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis Sicca", 
                "Eye Pain"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients of both genders\n\n          -  Age \u2265 18 years old\n\n          -  Give written informed consent to participate in the study after having been informed\n             of the study design, objectives and possible derived risks\n\n          -  Common mild to moderate dry eye symptoms. Persistent daily symptoms for more than\n             three months:\n\n          -  OSDI scale: 13-30\n\n          -  VAS scale: 2-7\n\n          -  Ocular tests in both eyes:\n\n          -  Corneal staining with fluorescein. Oxford scale > 0\n\n          -  Tear Breakup Time Test: (BUT) < 10 seconds\n\n          -  Schirmer test with anaesthesia < 10 mm/5min\n\n        Exclusion Criteria:\n\n          -  Pregnant or breastfeeding females or those with a positive pregnancy test.\n\n          -  Females of childbearing potential who will not use a medically acceptable\n             contraceptive method from selection and during the whole study.\n\n          -  Current relevant disease, including respiratory disease, cardiovascular, endocrine,\n             neurological, haematological, renal, neoplasic, hepatopathy, gastrointestinal\n             distress, hypertension, or infectious acute processes.\n\n          -  Past history of a chronic o recurring condition that could interfere with study\n             according to the investigator's judgement.\n\n          -  Concomitant use of other drugs with analgesic activity by any route of administration\n             at the enrolment period.\n\n          -  Changes in any ocular and/or systemic concomitant medication one month prior to the\n             study commencement and during the study development.\n\n          -  Changes on the preestablished artificial tears dosage 15 days prior to the study\n             commencement and during the study development.\n\n          -  Cyclosporine treatment initiation or changes in cyclosporine dosage or dosing regimen\n             during the 6 months prior to enrolment.\n\n          -  Previous history of drug hypersensitivity.\n\n          -  Use of contact lenses\n\n          -  Case history of drug or alcohol abuse or dependence.\n\n          -  Relevant abnormal laboratory results as judged by the investigator\n\n          -  Previous refractive surgery\n\n          -  Participation in a clinical trial within 2 months before the enrolment visit\n\n          -  Relevant ocular pathology judged by the investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01776658", 
            "org_study_id": "SYL1001_II"
        }, 
        "intervention": [
            {
                "arm_group_label": "SYL1001 eye drops dose A", 
                "description": "Ocular topical administration of SYL1001 for 10 consecutive days", 
                "intervention_name": "SYL1001", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Ocular topical administration of placebo for 10 consecutive days", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ocular pain", 
            "Dry Eye Syndrome", 
            "siRNA", 
            "RNAi", 
            "TRPV1"
        ], 
        "lastchanged_date": "January 23, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28040"
                    }, 
                    "name": "Hospital Universitario Cl\u00ednico San Carlos"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28040"
                    }, 
                    "name": "Fundaci\u00f3n Jim\u00e9nez D\u00edaz"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oviedo", 
                        "country": "Spain", 
                        "zip": "33012"
                    }, 
                    "name": "Instituto Oftalmol\u00f3gico Fern\u00e1ndez-Vega"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "vruz@sylentis.com", 
            "last_name": "Ver\u00f3nica Ruz, PhD"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Spain: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica"
            ]
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Changes from Baseline in the Ocular Pain Scores on the Visual Analog Scale (VAS) and in the Ocular Discomfort Scores on the Ocular Surface Disease Index (OSDI) as a Measure of SYL1001 Analgesic Effect versus Placebo.", 
                "safety_issue": "No", 
                "time_frame": "10 days + (4-10 days)"
            }, 
            {
                "measure": "Simple Corneal and Conjunctival Evaluation as a Measure of Safety and Tolerability using Ophthalmic Dyes and a Slit Lamp", 
                "safety_issue": "Yes", 
                "time_frame": "10 days + (4-10 days)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01776658"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Assessment of Adverse Events Appearance as a measure of SYL1001 tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "10 days + (96-240 hours)"
            }, 
            {
                "measure": "Evaluation of Vital Signs, Blood, Urine and Ocular Parameters Alterations (IOP, Visual Acuity, Anterior Segment Exploration) Possibly Related to the Investigational Product", 
                "safety_issue": "Yes", 
                "time_frame": "10 days + (96-240 hours)"
            }
        ], 
        "source": "Sylentis, S.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sylentis, S.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}